LENZ Signs an Exclusive License Agreement with Ji Xing for LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) to Treat Presbyopia in Greater China
Shots:
- LENZ to receive $15M up front & will be eligible to receive ~$95M in development, regulatory & commercial milestones along with royalty. Additionally, RTW will invest $10M in LENZ
- JI XING will be responsible for the development & commercialization of LNZ100 & LNZ101 in Greater China. In clinical trials, both products have shown that near-vision improvement correlates to aceclidine’s ability to maintain a pinhole pupil sweet spot for 7 hrs. & showed no loss & a slight trend toward a net gain in best-corrected distance vision, was well tolerated with no serious AEs
- The (INSIGHT) clinical trial will use as a confirmatory lead-in for the P-III trial which is expected to be initiated in H2’22
Ref: Businesswire | Image: Lenz
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
